National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.

Rapid Review

Commenced Completed Outcome
02/08/2016 24/08/2016 Full pharmacoeconomic evaluation recommended

Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.